– USA, CA – Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical-stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara Seymour to its board of directors.
“We are pleased to welcome Tamara to Artelo’s board of directors,” said Board Chair, Connie Matsui. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience guiding biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe her advice and insight will be instrumental to the Company’s development and growth.”
About Tamara Seymour
Tamara Seymour is a corporate finance veteran with three decades of experience in the biotech and life sciences industries. She has served as CFO in both public and venture-backed private companies at all stages of development. Ms. Seymour’s experience includes leading finance, investor relations, managed care and reimbursement, human resources, administration, and information technology. She has raised over $250 million in multiple private and public equity and debt financings, including spearheading an IPO.
“Now is an exciting time to be joining Artelo as it considers multiple strategies to advance and accelerate its non-clinical and clinical-stage programs,” said Tamara Seymour. “I look forward to working with the very capable team to realize even more of Artelo’s potential.”
In addition to her experience as an officer in public companies, Ms. Seymour was also a member of the Board of Directors and Chair of the Audit Committee of Beacon Discovery, Inc., a drug discovery company in San Diego, California that was recently acquired by Eurofins Scientific. Ms. Seymour is a certified public accountant. She received an MBA, with an emphasis in finance, from Georgia State University and earned her BBA, with an emphasis in accounting, from Valdosta State University.
About Artelo Biosciences
Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting lipid signaling pathways including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies.
For more information: https://artelobio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.